Arovella to present on tomorrow (4/04/2023)

Our preclinical biotech Investment, Arovella Therapeutics (ASX:ALA), will be presenting an “Explanatory Webinar” tomorrow - which should give us a great look at how the company’s allogeneic iNKT Cell Platform works.

Arovella’s Senior VP of Development and Translational Medicine, Dr Mini Bharathan, will be presenting with CEO and Managing Director, Dr Michael Baker.

To follow the presentation, click on the link below:

https://us02web.zoom.us/webinar/register/WN_q97UwBO3RTqQpaPwwzPSvw

We’ll be listening in.

ALA’s focus is on an “off-the-shelf” treatment that could make high end cancer treatments more widely available.

ALA has been busy progressing its cell therapy platform over the past year and we’re hoping to see its in vivo (mouse study) results soon.

This is a critical piece of validation for the treatment that it is working on in conjunction with ASX biotech giant Imugene (capped at $800M).

ALA says that it intends to release more data.

In anticipation of its upcoming progress, in February, we increased our Investment via ALA’s January capital raise at 2 cents.

This is in keeping with our view that if ALA is successful in taking any of its three different preclinical treatments to a Phase 1 study, this could secure a significant re-rate for the company.

ALA’s cancer fighting technology leverages the special characteristics of iNKT cells which have been shown to contribute to a spontaneous secondary remission in mice in a previous study.

In simple terms - ALA’s treatment persists in mice, killing cancer in the animals if it threatens to return.

This is a very remarkable phenomena.

We expect ALA will provide further insights into how its iNKT cell treatments are different to existing T-cell therapies - which are prohibitively expensive, costing as much as $500,000 per patient.

If ALA can make a breakthrough here - we think this would be well received by the market.

What’s next for ALA?

We want to see ALA scale up the manufacturing of its treatment - a key hurdle for the company.

Beyond that, we want to see the in vivo data which (we hope) demonstrates the effectiveness of the combined ALA+Imugene treatment. The presentation of conference data/academic research could further enhance the credentials of ALA’s treatment.